Avelumab plus axitinib vs. sunitinib for advanced renal-cell carcinoma

被引：1
|
作者：
Zhang, Yue [1 ]
Wu, Shenhong [1 ]
机构：
[1] Stony Brook Univ Hosp, Div Hematol & Oncol, Stony Brook, NY USA
来源：
TRANSLATIONAL CANCER RESEARCH | 2019年 / 8卷
关键词：
OPEN-LABEL; MULTICENTER; NIVOLUMAB;
D O I：
10.21037/tcr.2019.06.39
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S585 / S588
页数：4
相关论文
共 50 条
  • [11] JAVELIN renal 101: A randomized, phase III study of avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC)
    Motzer, R. J.
    Penkov, K.
    Haanen, J. B. A. G.
    Rini, B. I.
    Albiges, L.
    Campbell, M. T.
    Kollmannsberger, C. K.
    Negrier, S.
    Uemura, M.
    Lee, J. L.
    Gurney, H.
    Berger, R.
    Schmidinger, M.
    Larkin, J.
    Atkins, M. B.
    Wang, J.
    Robbins, P. B.
    Chudnovsky, A.
    Di Pietro, A.
    Choueiri, T. K.
    ANNALS OF ONCOLOGY, 2018, 29 : 724 - 724
  • [12] A Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma
    Meyo, Manuela Tiako
    Chen, Jeanne
    Goldwasser, Francois
    Hirsch, Laure
    Huillard, Olivier
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2022, 18 : 683 - 698
  • [13] Subgroup analysis from JAVELIN Renal 101: Outcomes for avelumab plus axitinib (A plus Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).
    Choueiri, Toni K.
    Motzer, Robert J.
    Campbell, Matthew T.
    Alekseev, Boris Y.
    Uemura, Motohide
    Kollmannsberger, Christian K.
    Gravis, Gwenaelle
    Bjarnason, Georg A.
    Gurney, Howard
    Chung, Jinsoo
    Haanen, John B. A. G.
    Rini, Brian I.
    Larkin, James M. G.
    Schmidinger, Manuela
    Nole, Franco
    Chudnovsky, Aleksander
    Huang, Bo
    Hariharan, Subramanian
    di Pietro, Alessandra
    Albiges, Laurence
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [14] Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
    Motzer, R. J.
    Tannir, N. M.
    McDermott, D. F.
    Frontera, O. Aren
    Melichar, B.
    Choueiri, T. K.
    Plimack, Elizabeth R.
    Barthelemy, P.
    Porta, C.
    George, S.
    Powles, T.
    Donskov, F.
    Neiman, V.
    Kollmannsberger, C. K.
    Salman, P.
    Gurney, H.
    Hawkins, R.
    Ravaud, A.
    Grimm, M. -O.
    Bracarda, S.
    Barrios, C. H.
    Tomita, Y.
    Castellano, D.
    Rini, B. I.
    Chen, A. C.
    Mekan, S.
    McHenry, M. B.
    Wind-Rotolo, M.
    Doan, J.
    Sharma, P.
    Hammers, H. J.
    Escudier, B.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (14): : 1277 - 1290
  • [15] Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
    Choueiri, T. K.
    Powles, T.
    Burotto, M.
    Escudier, B.
    Bourlon, M. T.
    Zurawski, B.
    Juarez, V. M. Oyervides
    Hsieh, J. J.
    Basso, U.
    Shah, A. Y.
    Suarez, C.
    Hamzaj, A.
    Goh, J. C.
    Barrios, C.
    Richardet, M.
    Porta, C.
    Kowalyszyn, R.
    Feregrino, J. P.
    Zolnierek, J.
    Pook, D.
    Kessler, E. R.
    Tomita, Y.
    Mizuno, R.
    Bedke, J.
    Zhang, J.
    Maurer, M. A.
    Simsek, B.
    Ejzykowicz, F.
    Schwab, G. M.
    Apolo, A. B.
    Motzer, R. J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (09): : 829 - 841
  • [16] Integrating peripheral biomarker analyses from JAVELIN Renal 101: Avelumab plus axitinib (A plus Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).
    Choueiri, Toni K.
    Donahue, Amber C.
    Rini, Brian I.
    Powles, Thomas
    Haanen, John B. A. G.
    Larkin, James
    Mu, Xinmeng Jasmine
    Pu, Jie
    Thomaidou, Despina
    Di Pietro, Alessandra
    Robbins, Paul B.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [17] Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial
    Bilen, Mehmet A.
    Rini, Brian, I
    Voss, Martin H.
    Larkin, James
    Haanen, John B. A. G.
    Albiges, Laurence
    Pagliaro, Lance C.
    Voog, Eric G.
    Lam, Elaine T.
    Kislov, Nikolay
    McGregor, Bradley A.
    Lalani, Aly-Khan A.
    Huang, Bo
    di Pietro, Alessandra
    Krulewicz, Stan
    Robbins, Paul B.
    Choueiri, Toni K.
    CLINICAL CANCER RESEARCH, 2022, 28 (04) : 738 - 747
  • [18] Randomized phase III trial of avelumab plus axitinib vs sunitinib as first-line treatment for advanced renal cell carcinoma: JAVELIN renal 101 Japanese subgroup analysis
    Uemura, M.
    Tomita, Y.
    Miyake, H.
    Hatakeyama, S.
    Kanayama, H-O.
    Numakura, K.
    Takagi, T.
    Kato, T.
    Eto, M.
    Obara, W.
    Uemura, H.
    Motzer, R. J.
    Fujii, Y.
    Kamei, Y.
    Oya, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [19] Efficacy of avelumab plus axitinib vs sunitinib by IMDC risk group in advanced renal cell carcinoma (aRCC): extended follow-up results from JAVELIN Renal 101
    Haanen, John
    Larkin, James
    Choueiri, Toni
    Albiges, Laurence
    Rini, Brian
    Atkins, Michael
    Schmidinger, Manuela
    Penkov, Konstantin
    Thomaidou, Despina
    Wang, Jing
    Mariani, Mariangela
    di Pietro, Alessandra
    Motzer, Robert
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 51 - 51
  • [20] Re: Nivolumab plus Cabozantinib Versus Sunitinib for Advanced Renal-cell Carcinoma
    不详
    EUROPEAN UROLOGY, 2021, 80 (02) : 256 - 257
12345